Business News • PR NewsWire • Enesi Pharma's ImplaVax®-Enabled, Solid-Dose Modified Live Virus Vaccine Produces Neutralising Antibody and T-Cell Responses Equivalent to Liquid Vaccine Delivered via Needle and Syringe

Enesi Pharma's ImplaVax®-Enabled, Solid-Dose Modified Live Virus Vaccine Produces Neutralising Antibody and T-Cell Responses Equivalent to Liquid Vaccine Delivered via Needle and Syringe

Enesi Pharma's ImplaVax®-Enabled, Solid-Dose Modified Live Virus Vaccine Produces Neutralising Antibody and T-Cell Responses Equivalent to Liquid Vaccine Delivered via Needle and Syringe

OXFORD, England, Sept. 29, 2020 /PRNewswire/ -- Enesi Pharma ("Enesi"), an innovative biotechnology company developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens enabled by its ImplaVax® technologies, is delighted to report positive...

View More : https://www.prnewswire.com:443/news-releases/enesi-pharmas-implavax-enabled-solid-dose-modified-live-virus-vaccine-produ...

Releted News by prnewswire

Dutch Amarna Therapeutics enters research collaboration with Spanish FPS, examining the efficacy of its SV40-based SVec™ gene delivery vector platform technology in diabetes mellitus type 1 and multiple sclerosis

Immunovia Announces Positive Results from the IMMray™ PanCan-d Verification Study

Transform Materials Converts Abundant Natural Gas into High-Value Hydrogen and Acetylene

Color Star Technology Announces Change in Ticker Symbol

Purepoint Uranium Group Inc.: Upcoming Program at Hook Lake